The CAPItello-281 trial indicated that the addition of capivasertib to androgen deprivation therapy (ADT) + abiraterone improves radiographic progression-free survival (rPFS) compared to ADT + abiraterone + placebo in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC) (33.2 vs 25.7 months)1. Symptomatic skeletal event-free survival (SSE-FS) also showed a non-statistically significant trend (42.5 vs 37.3 months) in favor of the…
Letter to the Editor: Capivasertib plus abiraterone in PTEN-deficient metastatic hormone sensitive prostate cancer: CAPItello-281 phase III study
Annals of Oncology | | Fabio Turco, Ursula Maria Vogl, Hui Ming Lin, Martino Pedrani, Gianmarco Leone, Silke Gillessen
Topics: prostate-cancer, blood-cancer, clinical-trials, research